Sepsis Diagnostics Market worth $1.22 billion by 2031
The report "Sepsis Diagnostics Market by Technology (Blood Culture, PCR, Immunoassay), Product (Culture, Assay, Instruments), Sample (Serum, blood), Test Type (Lab, POC), Pathogen (Bacterial), End User (Hospital, Pathology & Reference Labs) - Global Forecast to 2031" is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%.
Browse 400 market data Tables and 310 Figures spread through 500 Pages and in-depth TOC on "Sepsis Diagnostics Market, by Technology (Blood Culture, PCR, Immunoassay), Product (Culture, Assay, Instruments), Sample (Serum, blood), Test Type (Lab, POC), Pathogen (Bacterial), End User (Hospital, Pathology & Reference Labs) - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/sepsis-diagnostic-market-92673155.html
The global sepsis diagnostics market is growing steadily, driven by the high incidence of sepsis and bloodstream infections, increased adoption of rapid molecular and syndromic diagnostics, greater focus on antimicrobial stewardship, and broader use of biomarker-based testing. The market is also supported by the growing need for early sepsis detection, faster pathogen identification, antimicrobial resistance profiling, and improved clinical decision-making in emergency departments, ICUs, and hospital laboratories.
Assays & reagent kits accounted for the largest share of the global sepsis diagnostics market, by product, in 2025.
By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest share, driven by their recurring use across blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Growing demand for pathogen detection kits, sepsis biomarker assays, PCR-based reagents, and syndromic testing panels continues to support this segment's dominance. Instruments also held a significant share, driven by the increasing installation of automated blood culture systems, molecular diagnostic platforms, mass spectrometry systems, and clinical chemistry analyzers in hospitals and reference laboratories.
Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025.
By technology, the market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry and blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. Molecular diagnostics is expected to grow strongly over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for faster pathogen identification and resistance marker detection.
Bacterial sepsis accounted for the largest share of the sepsis diagnostics market, by pathogen type, in 2025.
By pathogen type, the market is segmented into bacterial sepsis, fungal sepsis, and other pathogen types, including parasitic and polymicrobial sepsis. In 2025, bacterial sepsis accounted for the largest share, supported by the high burden of bacterial bloodstream, hospital-acquired, and ICU-related infections, as well as the strong clinical need for pathogen identification and antimicrobial susceptibility testing. Gram-negative and Gram-positive bacterial sepsis remain key subsegments due to their significant role in severe infections and antimicrobial resistance concerns. Fungal sepsis is expected to attract attention as cases rise among immunocompromised patients, oncology patients, transplant recipients, and critically ill ICU patients.
Laboratory tests accounted for the largest share of the sepsis diagnostics market, by test type, in 2025.
By test type, the sepsis diagnostics market is segmented into laboratory and point-of-care tests. In 2025, laboratory tests accounted for the largest share, driven by the central role of hospital laboratories, microbiology departments, and reference laboratories in blood culture testing, molecular diagnostics, immunoassays, antimicrobial susceptibility testing, mass spectrometry, and clinical chemistry testing. Point-of-care tests are expected to grow rapidly due to rising demand for rapid sepsis screening, emergency department testing, ICU-based decision support, and decentralized biomarker-based assessment.
Whole blood accounted for the largest share of the sepsis diagnostics market, by sample type, in 2025.
By sample type, the sepsis diagnostics market is segmented into whole blood and serum. In 2025, whole blood accounted for the largest share, supported by its established use in blood culture testing, molecular pathogen detection, bloodstream infection diagnosis, and sepsis-related microbiology workflows. Whole blood remains central to sepsis diagnosis because detecting bloodstream infections and identifying pathogens require direct or culture-based analysis of blood samples. Serum-based testing also holds an important share due to its use in immunoassays, inflammatory biomarker testing, host-response assessment, and clinical chemistry-based evaluation of sepsis severity.
Hospitals & specialty clinics accounted for the largest share of the sepsis diagnostics market, by end user, in 2025.
By end user, the market is segmented into hospitals and specialty clinics, pathology and reference laboratories, and research laboratories, academic institutes, and CROs. In 2025, hospitals and specialty clinics accounted for the largest share, driven by the high sepsis burden in emergency departments, ICUs, inpatient wards, and critical care settings. Hospitals are the primary users of blood culture systems, rapid molecular tests, clinical chemistry analyzers, blood gas analyzers, and antimicrobial stewardship-linked diagnostic workflows. Pathology and reference laboratories also play an important role by supporting high-volume infectious disease testing, confirmatory diagnostics, molecular testing, and outsourced microbiology services.
North America accounted for the largest regional share of the global sepsis diagnostics market in 2025.
The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America accounted for the largest share, driven by advanced hospital infrastructure, high adoption of automated blood culture systems and molecular diagnostics, strong antimicrobial stewardship initiatives, favorable adoption of rapid diagnostics, and the presence of leading diagnostic companies. Europe remains a significant market due to established microbiology laboratory networks, robust infectious disease testing infrastructure, and an increasing focus on sepsis management and antimicrobial resistance control. Asia Pacific is expected to grow fastest, driven by rising healthcare expenditure, expanding hospital infrastructure, a growing burden of infectious diseases and bloodstream infections, and increasing adoption of automated and molecular diagnostic platforms.
Key players in the sepsis diagnostics market include Biomérieux (France), Becton Dickinson and Company (US), Danaher Corporation (US), Diasorin S.P.A. (US), F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific, Inc. (US), Bruker Corporation (US), Abbott Laboratories (US), Sysmex Corporation (Japan), Siemens Healthineers (Germany), QIAGEN (Netherlands), Quidelortho Corporation (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Sepsis Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
